Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer.
about
Curcumin and Resveratrol as Promising Natural Remedies with Nanomedicine Approach for the Effective Treatment of Triple Negative Breast CancerInfracentimetric HER-2 positive breast tumours-review of the literatureTowards a targeted multi-drug delivery approach to improve therapeutic efficacy in breast cancerPreliminary Development and Evaluation of an Algorithm to Identify Breast Cancer Chemotherapy Toxicities Using Electronic Medical Records and Administrative Data.Inflammatory (B) symptoms are independent predictors of myelosuppression from chemotherapy in Non-Hodgkin Lymphoma (NHL) patients--analysis of data from a British National Lymphoma Investigation phase III trial comparing CHOP to PMitCEBO.Chemotherapy use and risk of bone marrow suppression in a large population-based cohort of older women with breast and ovarian cancer.Thrombocytopenia in adult cancer patients receiving cytotoxic chemotherapy: results from a retrospective hospital-based cohort study.Incidence of Neutropenia in Veterans Receiving Lung Cancer Chemotherapy: A Comparison of Administrative Coding and Electronic Laboratory Data.PSMA-targeted theranostic nanoplex for prostate cancer therapy.Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study.Pilot study on developing a decision support tool for guiding re-administration of chemotherapeutic agent after a serious adverse drug reactionHospital-based health care use correlates with incidence of adverse events among elderly Medicare patients treated in adjuvant chemotherapy trials (Alliance 70802).Understanding chemotherapy treatment pathways of advanced colorectal cancer patients to inform an economic evaluation in the United Kingdom.Investigation of adverse-event-related costs for patients with metastatic breast cancer in a real-world settingRisk of hospitalization according to chemotherapy regimen in early-stage breast cancer.Societal cost-effectiveness analysis of the 21-gene assay in estrogen-receptor-positive, lymph-node-negative early-stage breast cancer in Japan.Management of ErbB2-positive breast cancer: insights from preclinical and clinical studies with lapatinib.Nanoplex delivery of siRNA and prodrug enzyme for multimodality image-guided molecular pathway targeted cancer therapyContraindicated use of bevacizumab and toxicity in elderly patients with cancerCost-effectiveness of a 21-gene recurrence score assay versus Canadian clinical practice in women with early-stage estrogen- or progesterone-receptor-positive, axillary lymph-node negative breast cancer.Health system costs for stage-specific breast cancer: a population-based approach.Gene polymorphisms in cyclophosphamide metabolism pathway,treatment-related toxicity, and disease-free survival in SWOG 8897 clinical trial for breast cancer.Genomic testing and therapies for breast cancer in clinical practice.Transition from curative to palliative care in cancer.Multivariable regression analysis of febrile neutropenia occurrence in early breast cancer patients receiving chemotherapy assessing patient-related, chemotherapy-related and genetic risk factorsChemotherapy-related hospitalization among community cancer center patientsUse and Effectiveness of Intraperitoneal Chemotherapy for Treatment of Ovarian CancerTradeoffs of using administrative claims and medical records to identify the use of personalized medicine for patients with breast cancer.A Clinical Prediction Model to Assess Risk for Chemotherapy-Related Hospitalization in Patients Initiating Palliative Chemotherapy.Polymeric composite devices for localized treatment of early-stage breast cancer.The impact of a supplementary medication review and counselling service within the oncology outpatient settingGene expression profile testing for breast cancer and the use of chemotherapy, serious adverse effects, and costs of careResponding to Acute Care Needs of Patients With Cancer: Recent Trends Across ContinentsFactors Associated With Unplanned Hospitalizations Among Patients With Nonmetastatic Colorectal Cancers Intended for Treatment in the Ambulatory Setting.Sensitivity of International Classification of Diseases codes for hyponatremia among commercially insured outpatients in the United States.Does value mean quality? The payer's perspectiveSymptom-related emergency department visits and hospital admissions during ambulatory cancer treatmentAdverse Health Events Following Intermittent and Continuous Androgen Deprivation in Patients With Metastatic Prostate Cancer.Utilization and Toxicity of Alternative Delivery Methods of Adjuvant Chemotherapy for Ovarian Cancer.Is Age-targeted full-field digital mammography screening cost-effective in emerging countries? A micro simulation model.
P2860
Q26744566-CAE554CC-CC38-45ED-9054-4AD9A94F0B3FQ26774597-FE38F3A5-C6C8-48E9-AFF6-0D6DC6AB65ADQ28291499-9C6536C2-AEF1-4577-9D26-67CD6A9B14D5Q30845285-5F59C107-4194-4D9B-8D86-7177257A02ECQ33384548-465AEE8B-64A2-481B-BC10-1AD5C5BEE735Q33389009-C63CCD79-4179-4F18-83F9-CEDB8ED3B9CFQ33398191-C879FE71-0CB1-4B58-B483-30F88D3BA2D3Q33557215-93A1B7D5-AF42-4F4A-9741-035059432BE3Q33791366-C20B4414-9FBD-488E-B269-9FCAA2BC53C2Q33824842-5E31527F-B85F-4846-A178-3A350C9C4E40Q33973091-78E79343-F5B6-42E7-ADCB-67A26D0BA303Q33992552-313D1F93-78A5-4C51-8CB9-295E8F624A93Q34059702-4238E351-B54C-43BA-93FA-7AB94E9CD3EEQ34127931-C932FFA2-8067-4049-AF05-8DD4711D1EF1Q34184798-F386A1FD-A203-44D9-A25A-1CE6E17552EAQ34196301-913D3F52-85C0-45AD-9D14-40927254B835Q34241118-51D65BFD-CB6D-4C75-A947-21F193B97FF1Q34348175-9C1D264C-317F-4E88-8835-BC3D9CA173CDQ34368413-16EB6B0D-B0F9-4856-A0CF-771518E4DEE5Q34431985-45B33C93-73A7-4CE7-9767-0B24899F7A7CQ34637835-7F6E8418-980C-4F56-B2B0-91188EC93327Q34682560-F1E55D5F-8169-45AD-A442-AA03A7594415Q34974164-BE0336ED-F5FD-4B91-A18A-201A755EE7FCQ34994134-BB3C24C7-F4F8-40E6-9B18-06B49665CC45Q35123683-7313FDC1-CDBB-4C54-A179-C8FE66C9019AQ35584511-D0F9CFC2-68FE-4FFE-BB61-6223082BDBD4Q36011137-F192D616-E733-45AF-86C1-5ECD42F54C40Q36060162-2D302AA9-A9DA-4AAC-A7AF-33B715DBA329Q36076727-EF03E71E-ED23-4045-9CE0-0E68C837BEB5Q36292985-39388C3D-43AC-4B2B-A275-FA1D0A66BA53Q36609997-E9CBE2FB-225C-46B6-A2FA-BACE6076A702Q36661690-EBEC8267-5519-43A4-8E34-F384A0A32E55Q36673445-28A0AE9D-1965-46FF-81D8-085969A25499Q36738038-F48455D3-F907-48D2-AC40-42C70399146AQ36749502-20C95342-4BA5-4DAD-84C4-C6E99B118BBEQ36835895-F1CCF729-0937-4B98-8565-58DCAC8BB7F8Q36847478-90ABA9E4-CB96-49AF-98B0-BC25B4D95B58Q36854835-D73AFD58-6489-4ED6-8C12-24A85100B4ECQ36932625-89F25BD9-761A-467A-AA9C-4E05DD998092Q37076741-53C4F350-C589-4BD5-B250-E251ED9DF39C
P2860
Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer.
description
2006 nî lūn-bûn
@nan
2006 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Frequency and cost of chemothe ...... e of women with breast cancer.
@ast
Frequency and cost of chemothe ...... e of women with breast cancer.
@en
type
label
Frequency and cost of chemothe ...... e of women with breast cancer.
@ast
Frequency and cost of chemothe ...... e of women with breast cancer.
@en
prefLabel
Frequency and cost of chemothe ...... e of women with breast cancer.
@ast
Frequency and cost of chemothe ...... e of women with breast cancer.
@en
P2093
P2860
P356
P1476
Frequency and cost of chemothe ...... e of women with breast cancer.
@en
P2093
A James O'Malley
Craig C Earle
Joseph P Newhouse
Juliana R Pakes
Michael J Hassett
P2860
P304
P356
10.1093/JNCI/DJJ305
P407
P577
2006-08-01T00:00:00Z